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A TH1 POLARIZING VACCINE FOR BOOSTING THE ANTITUMOR ACTIVITY
OF ADOPTIVELY TRANSFERRED T CELLS
Song, X.-T.1, Turnis, M.1, Zhou, X.1, Rollins, L.1, Hong, B.-X.3,
Rabinovich, B.2, Chen, S.-Y.M.3, Rooney, C.1, Gottschalk, S.1 1Baylor
College ofMedicine, Houston, TX; 2M.D. Anderson Cancer Center, Hous-
ton, TX; 3University of Southern California, Los Angeles, CA
Background:T cell therapies for several human cancers are showing
increasing success, and their effectiveness can be increased by prior
lymphodepletion of the host. This process, however, requires inten-
sive chemotherapy or radiation, producing significant morbidity,
and mortality. The aim of this project was to develop an adenoviral
vaccine to boost the expansion of adoptively transferred T cells with-
out systemic side effects. We show here that a vaccine, which 1) pro-
vides antigens, 2) inhibits the antigen presenting attenuator A20, and
3) encodes flagellin for Toll-like receptor (TLR) 5 activation, boosts
the expansion and antitumor effects of adoptively transferred T cells
in the B16-OVA tumor model.
Methods: Recombinant adenoviruses were constructed that express
A20-shRNA to silence A20 (Ad-shA20) or A20-shRNA and flagellin
(Ad-shA20-FL). B16-OVA tumor bearing mice were either vacci-
nated with 1) Ad-shA20-FL/Ad-OVA, 2) Ad-shA20/Ad-OVA, 3)
Ad-OVA or 4) Ad-shA20-FL before the adoptive of OVA-specific
T cells (OT-I T cells). Routine immunological assays were used to
determine the effects of vaccine/T-cell therapy. Bioluminescence
imaging was used to track infused OT-I T cells and knockout mice
were used for mechanistic studies.
Results: B16-OVA tumor bearing mice were vaccinated on day 5
with Ad-shA20-FL/Ad-OVA, Ad-shA20/Ad-OVA, or Ad-OVA
and received a single dose of OT-I T cells on day 7. Only the Ad-
shA20-FL/Ad-OVA vaccine induced significant expansion of OT-I
T-cells resulting in prolonged regression of B16-OVA tumors. In
contrast, injection of OT-I T cells or the Ad-shA20-FL/Ad-OVA
vaccine had only modest antitumor effects. Mechanistic studies re-
vealed that Ad-shA20-FL/Ad-OVA vaccination induced robust
Th1, Th2, and Th17 responses in B16-OVA bearing mice. Activa-
tion of Th1 T cells was critical for the observed effects since the
Ad-shA20-FL/Ad-OVA vaccine was ineffective in activating and ex-
panding infused OT-I T-cells in IL12-/- (Th1 deficient) but not in
RORgt-/- (Th17 deficient) mice.
Conclusion: This study shows that a TH1-polarizing vaccine effi-
ciently boosts the proliferation and antitumor activity of adoptively
transferred T cells obviating the need of lymphodepletion with cyto-
toxic agents. Hence, this combined vaccine/T-cell therapy should al-
low the ex vivo generation and reinfusion of high affinity T cells
against weak tumor antigens thereby broadening the range of tumors
that will be susceptible to immune therapy.260
DENDRITIC-CELL BASED TUMOR VACCINATION IN PROSTATE AND RE-
NAL CELL CANCER: SYSTEMATIC REVIEW AND POST-HOC ANALYSIS
Draube, A.1, Klein-Gonzalez, N.1, Rademacher, S.1, Brillant, C.2,
Hellmich, M.3, von Bergwelt-Baildon, M.1 1University Hospital of Co-
logne, Germany; 2University Hospital of Cologne, Germany; 3University
Hospital of Cologne, Germany
Dendritic cells (DC) as natures adjuvant are a candidate APC for
post transplant immune intervention. So far, more than 200 – mostly
small phase I/II – clinical trials usingDChave been published in can-
cer. Nevertheless heterogeneity of vaccination strategies, non stan-
dardized cellular products and the lack of standard criteria for
clinical and immunological responses make it difficult to draw solid
conclusions from single trials. Prostate and renal cell cancer (RCC),
are regularly infiltrated by antigen-specific immune cells and are
considered susceptible to immunotherapy. They have therefore
been studied intensively as targets of DC-based interventions.
Therefore we chose these entities for a systematic review of DC
based tumor vaccines using single patient data to perform compre-
hensive statistic analyses. We searched the Medline database from
January 2000 to December 2007. Articles published with mixed en-
tities, follow-up studies and trials using allogeneic DC were ex-cluded. Twenty four studies in prostate cancer (15) and RCC (9)
were analyzed in detail comprising a total of 445 patients.
Available individual patient data of 348 patients were used for post
hoc analyses. DC types used for the vaccination strategies were im-
mature monocyte derived DC, mature, monocyte derived DC, and
density-grade enriched DC in 8, 12 and 4 studies respectively. For
antigen delivery peptides, proteins and tumor lysates were utilized
in 33%, 21% and 25% of the patients respectively. Comparison of
quality control standards and DC dose revealed striking differences
between the studies. Chisquare tests revealed cellular immune re-
sponse, DC dose and route of vaccination to have a significant influ-
ence on the clinical benefit rate (CBR: CR, PR, MR, SD). Analyses
stratified by studies confirmed a significant odds ratio for the associ-
ation of cellular immune response andCBR, andDCdose withCBR,
both in prostate cancer andRCC.Taken together, this systematic re-
view disclosed a strong heterogeneity regarding vaccine dose, DC
type, antigen delivery, route and quality controls. However, as
a ‘proof of principle’ post-hoc analyses on individual-patient levels
revealed an association between the induction of cellular immune re-
sponse and clinical benefit rate both for prostate cancer and RCC.
To our knowledge this is the first systematic review demonstrating
statistically significant effects of DC based vaccines further underlin-
ing the potential of this treatment strategy.261
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH A
REDUCED-INTENSITY CONDITIONING REGIMEN (RIST) FOR THE TREAT-
MENT OF SOLID TUMORS: A SINGLE-INSTITUTE EXPERIENCE
Kamiyama, Y.1, Makimoto, A.2, Kim, S.-W.1, Yakushijin, K.1,
Hosono, A.2, Ueno, N.1, Fukuhara, S.1, Hiramoto, N.1, Asakura, Y.1,
Kurosawa, S.1, Fukuda, T.1, Mori, S.1, Tanosaki, R.1, Heike, Y.1,
Takaue, Y.1 1National Cancer Center Hospital, Tokyo, Japan; 2National
Cancer Center Hospital, Tokyo, Japan
Objective. RIST has been established as a standard therapy for
various hematologic malignancies. However, its feasibility in pa-
tients with solid tumors has not been well evaluated, and thus we
conducted a single-institute, retrospective study.
Patients andMethods. A total of 44 patients with various advanced
solid tumors underwent RIST from a related donor (41 sibling do-
nors; 38 HLA-matched and 6 one-locus-mismatched donors) be-
tween April 2000 and August 2006. Most were enrolled in various
prospective studies, and efficacy data for colorectal cancer and renal
cancer have been published previously (Transplantation 78:1740,
2004; Exp Hematol 32:599, 2004). This follow-up retrospective
analysis particularly focused on the overall feasibility of the proce-
dure. The median age of the patients was 43.5 years (range 20-61).
Their diseases were renal cell cancer (RCC: 8 mixed cell, 6 clear
cell, 2 granular cell and 1 papillary), pancreatic cancer (4), rhabdo-
myosarcoma (3), colorectal cancer (2), bile duct cancer (2), Bellini
duct cancer (2), and others(13). All but one patient, who had PR
small cell lung cancer, were in recurrent or primary refractory tumor.
The conditioning regimens were Flu (180 mg/m2)/BU(8 mg/kg
po)/ATG (Thymoglobulin 5 mg/m2) (19), Flu/BU (10), cladribi-
ne(0.66 mg/kg)/BU (9) and cladribine/BU/ATG (6). The primary
agent for GVHD prophylaxis was cyclosporine, and 4 patients also
received short-term methotrexate.
Results. All patients achieved hematological engraftment at a me-
dian of 11 days (range, 6-20). At 30 days and 90 days after transplan-
tation, 10 of the 18 and 10 of the 11 evaluable patients achieved
complete donor chimerism. Twenty-one patients developed acute
GVHD at a median of 28 days (range, 8-157), including 19 grade
2-4 and 10 grade 3-4. Seventeen developed chronic GVHD at a me-
dian of 114 days (range, 94-277). Therapy-related mortality (TRM)
was 9% (2 acute GVHD, 1 ARDS and 1 hemorrhagic shock), and 40
died from tumor progression. The median follow-up time was 167
days (range 14-1449). The overall survival rate at 2 years was 11%
in the whole group, while patients with RCC (clear cell 33%, all
other types 22%) had a higher rate of 25% (p\0.0001).
Conclusion. Although these findings suggest that RIST is feasible
in patients with refractory solid tumor, the ultimate usefulness of
RIST should be balanced against recently developed promising
new agents.
